This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NEOGEN (NEOG) Fortifies Global Position via Megazyme Buyout
by Zacks Equity Research
NEOGEN's (NEOG) buyout of Megazyme is expected to strengthen its Food Safety business worldwide.
Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.
Henry Schein (HSIC) Grows Inorganically, Closes JV, Buys Stake
by Zacks Equity Research
The developments are expected to strengthen Henry Schein's (HSIC) presence in high potential and still-untapped markets.
Hologic (HOLX) Completes SOMATEX Buyout, Expands Portfolio
by Zacks Equity Research
Hologic (HOLX) to expand biopsy portfolio as well as enhance patient experience via the SOMATEX buyout.
DENTSPLY (XRAY) Acquires Byte to Boost Clear Aligner Business
by Zacks Equity Research
DENTSPLY (XRAY) acquires Byte to strengthen presence in the lucrative clear aligner space.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health
by Zacks Equity Research
FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform
Why You Should Retain Veeva (VEEV) in Your Portfolio Now?
by Zacks Equity Research
Investor confidence/optimism is high on Veeva (VEEV) stock, driven by its solid prospects.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently launched products as well as potential in its U.S. Surgical Support business.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, driven by its solid prospects.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.
Integra (IART) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Integra (IART) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
5 Soaring MedTech Stocks to Buy for More Growth in 2021
by Urmimala Biswas
We have selected five MedTech growth stocks with further rooms for improvement in 2021.
Teleflex (TFX) Completes Buyout of Hemostatic Goods Producer
by Zacks Equity Research
Teleflex (TFX) to leverage its strength in enhancing clinical efficacy and patient safety via the recent buyout.
Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.
10 Top-Performing Stocks of the S&P 500 ETF in 2020
by Sanghamitra Saha
If a Santa Claus rally grips Wall Street in the final days of December, the S&P 500 could see smart gains in 2020 despite the COVID-19 outbreak. These stocks helped the index to hit highs this year.
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock on the back of its solid prospects.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
IDEXX (IDXX) Gains on CAG Sales, Global Growth Remains Robust
by Zacks Equity Research
IDEXX (IDXX) sees sturdy gains in CAG Diagnostics recurring revenues, supported by high organic gains in both U.S. and International markets.
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2021
by Zacks Equity Research
Four large-cap MedTech stocks are currently flourishing on the back of several positive developments
5 MedTech Stocks That Have Outperformed the Industry in 2020
by Debanjana Dey
Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
The Zacks Analyst Blog Highlights: L Brands, The Trade Desk, IDEXX Laboratories, NVIDIA and CrowdStrike
by Zacks Equity Research
The Zacks Analyst Blog Highlights: L Brands, The Trade Desk, IDEXX Laboratories, NVIDIA and CrowdStrike